Schizophrenia is recognized to be a highly heterogeneous disease at various levels, from
genetics to clinical manifestations and treatment sensitivity. This heterogeneity is also …

Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

Obesity represents an important public health concern because it substantially increases the
risk of multiple chronic diseases and thereby contributing to a decline in both quality of life …

Studies performed in schizophrenia patients have generally suggested the presence of a
compromised antioxidant system, but this is not always consistent with specific observed …

The atypical antipsychotics (AAPs) have been used as first-line drugs in psychiatric practice
for a wide range of psychotic disorders, including schizophrenia and bipolar mania. While …

While neurotransmitter dysfunction represents a key component in mental illnesses, there is
now a wide agreement for a central pathophysiological hub that includes hormones …

The use of antipsychotic drugs for the treatment of mood disorders and psychosis has
increased dramatically over the last decade. Despite its consumption being associated with …

Parkinson's disease is caused due to free radical generation in dopamine neurons leading
to oxidative stress induced damage. The aim of this work was to ameliorate the free radical …

Berberine due to its antioxidant properties, has been used around the globe significantly to
treat several brain disorders. Also, oxidative stress is a pathological hallmark in …

Background Metabolic syndrome (MetS) is a constellation of factors including abdominal
obesity, hyperglycemia, dyslipidemias, and hypertension that increase morbidity and …